[Huitai Medical: The company's current production and operation conditions are in good condition, product market coverage has been further improved, and R&D capabilities have been continuously enhanced] On October 23, Huitai Medical (688617.SH) released an announcement on the company's recent production and operation conditions. The company's current production and operation conditions are in good condition, product market coverage has been further improved, and R&D capabilities have been continuously enhanced. In the domestic market, the company will continue to improve the coverage and admission penetration rate of vascular interventional products by relying on accurate data analysis and key solutions; in the field of electrophysiology, with the successive implementation of pulse atrial fibrillation treatment charging projects and centralized procurement, the company will continue to accelerate the pace of access to pulse ablation consumables. In terms of the international market, the company's PCI product line will continue to leverage its core advantages in international business and continuously improve complex PCI and CTO overall solutions; the electrophysiology product line's three-dimensional electrophysiology systems and PFA solutions have begun to be installed globally; the peripheral product line continues to promote registration and market access layout in key countries, and continues to improve the construction of the global registration system to accelerate the CE and key country registration processes. The company will continue to improve system capabilities commensurate with its business scale. In terms of R&D registration, we will strengthen project process management and clinical resource coordination, improve the connection mechanism from clinical research to registration and certification, and improve the iteration efficiency and registration transformation capabilities of products under development; in terms of marketing and clinical services, we will improve regional coverage and service efficiency to support terminal volume expansion; in terms of quality and compliance, we will improve quality control covering R&D, registration, production, and circulation, and strengthen compliance management; in terms of informatization, we will promote digital construction and improve the collaborative efficiency of supply chain, production planning, and business analysis. The company will arrange investments step by step and rhythmically based on the overall strategic layout to provide support for sustainable business growth.